Cargando…
Therapeutic potential of HIV protease-activable CASP3
Development of a therapeutic application of CASP3/caspase 3/CPP32, an executor of apoptosis, has been challenging because regulation of its activation is complicated. This study aimed to inhibit cancer cell growth and human immunodeficiency virus type 1 (HIV-1) propagation through a CASP3 mutant, CA...
Autores principales: | Miyauchi, Kosuke, Urano, Emiko, Takizawa, Mari, Ichikawa, Reiko, Komano, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323887/ https://www.ncbi.nlm.nih.gov/pubmed/22496955 http://dx.doi.org/10.1038/srep00359 |
Ejemplares similares
-
Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation
por: Sainski, Amy M., et al.
Publicado: (2014) -
Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation
por: Sainski, Amy M., et al.
Publicado: (2014) -
Casp8p41 and HIV
por: Cummins, Nathan W., et al.
Publicado: (2015) -
HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome
por: Natesampillai, Sekar, et al.
Publicado: (2018) -
Association Between a Polymorphism in CASP3 and CASP9 Genes and Ischemic Stroke
por: Lee, Bae Youl, et al.
Publicado: (2017)